The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis

Abstract

Objectives To conduct a systematic review and meta-analysis to evaluate the prevalence of thyroid disorders in COVID-19 patients. Data sources Scopus, PubMed, ISI Web of Science, and Google Scholar databases were used in this review. We also consider the results of grey literature. Study selections Cohort, cross-sectional, and case-control studies were included. Data extraction and synthesis The required data were extracted by the first author of the article and reviewed by the second author. The Pooled prevalence of outcomes of interest was applied using the meta-prop method with a pooled estimate after Freeman-Tukey Double Arcsine Transformation to stabilize the variances. Outcomes and measured The different thyroid disorders were the main outcomes of this study. The diseases include non-thyroidal illness syndrome, thyrotoxicosis, hypothyroidism, isolated elevated free T4, and isolated low free T4. Results Eight articles were included in our meta-analysis(Total participants: 1654). The pooled prevalence of events hypothyroidism, isolated elevated FT4, isolated low FT4, NTIS, and thyrotoxicosis were estimated (Pooled P = 3%, 95% CI:2–5%, I2: 78%), (Pooled P = 2%, 95% CI: 0–4%, I2: 66%), (Pooled P = 1%, 95% CI: 0–1%, I2: 0%), (Pooled P = 26%, 95% CI: 10–42%, I2: 98%), and (Pooled P = 10%, 95% CI: 4–16%, I2: 89%), respectively. Conclusion Thyroid dysfunction is common in COVID-19 patients, with a high prevalence of non-thyroidal illness syndrome (NTIS) and thyrotoxicosis. Our meta-analysis found a 26% prevalence of NTIS and a 10% prevalence of thyrotoxicosis. Systematic review registration PROSPERO CRD42022312601.

Prevalence of hyperthyroidism and hypothyroidism in liver transplant recipients and associated risk factors

“…As COVID-19 may induce changes in thyroid function, comparing liver transplant recipients included during the pandemic with controls included before the pandemic may potentially impact the results 33 , 34 . However, access to COVID-19 tests was free and unrestricted for the public in Denmark, and we had access to all test results.…”

Thyroid dysfunction in the wake of Omicron: understanding its role in COVID-19 severity and mortality

“…Notably, only the decrease in FT4 levels in critically ill patients reached statistical significance. A recent meta-analysis found that among COVID-19 patients, ESS was the most prevalent thyroid disease with a pooled prevalence of 26%, followed by thyrotoxicosis and hypothyroidism, with pooled prevalences of 10% and 3%, respectively ( 3 ). In contrast, our study observed a different pattern.…”

“…Within the endocrine system, ACE2 is most abundantly present in the testicles, followed by the thyroid and the hypothalamus. The presence of ACE2 in the thyroid renders it a viable target for viral entry ( 3 ). Autopsy samples procured from the thyroid gland post-mortem have demonstrated that SARS-CoV-2 can directly infect the thyroid gland, the direct viral insult combined with an intense immune response may trigger or worsen thyroid conditions in predisposed individuals ( 4 , 5 ).…”

“…Existing perspectives suggest that abnormal thyroid function can manifest during the active phase of COVID-19 and persist into the convalescence phase ( 7 ). ESS is most prevalent among COVID-19 patients ( 3 ) and has been identified as an independent risk factor for disease severity ( 8 ). Furthermore, a reduction in FT3 levels has been independently associated with all-cause mortality in patients with severe or critical COVID-19 ( 9 ).…”